Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: RR — 15 Participants

Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants

Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473

Primary: Overall Survival — 13.4 month

Primary: Overall Survival — 12; 11; 13 participants

Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants

Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants

Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders

Primary: Response Rate — 0 percentage of patients responding

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Pathologic Complete Response (pCR) Rate — 7 Participants

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants

Primary: Objective Response Rate (ORR) — 3.92 Participants (%)

Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants

Primary: Progression Free Survival (PFS) — 6.34; 6.74 Months — p=0.698

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Overall Survival (OS) — 11.96 Months

Primary: Progression-free Survival (PFS) — 0 Participants

Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants

Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: Progression-free Survival — 4.7; 5.1 months

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Phase 1b — 6; 2 Participants

Primary: Progression-free Survival (PFS) — 5.257 months